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Abstract 
Controlled release tablets having near zero-order release of 
diclofenac sodium water soluble drug were prepared using guar gum 
(GG) in matrix core and Hydroxy Propyl Cellulose (HPC), Hydroxy 
Propyl Methyl Cellulose (HPMCK4M) and Sodium Carboxy Methyl 
Cellulose (Na CMC) as barrier layers. The optimum ratio of drug: 
guar gum was found to be 1:1, anionic GG in the matrix core and 
anionic Na CMC as barrier layers resulted in near zero order release 
of diclofenac sodium. Different dissolution models were applied to 
drug release data in order to evaluate release mechanisms and 
kinetics. The nature of drug release from matrix tablets and layered 
matrix tablets followed non-Fickian diffusion and super case II 
mechanism respectively. Mean dissolution time (MDT) for the 
formulations MT-GG and MLT-06 were found to be 3.65h and 
16.57h, while Dissolution Efficiency (DE8%) decreases, indicating 
that the release of drug is slower from layered matrix tablets. On the 
basis of in vitro release data, MLT-06 was subjected to 
bioavailability studies. The in-vivo characterization of diclofenac 
sodium in human volunteers from formulation MLT-06 showed 
delayed Tmax unaltered bio availability indicating a slow and 
controlled release of the drug from layered matrix tablets.  
Key words: Diclofenac sodium, Matrix and layered matrix tablets, 
Controlled released. 
 
Introduction 
Oral ingestion has long been the most convenient 
and commonly employed route of drug delivery 
due to its ease of administration and flexibility in 
the design of the dosage form. There are many 
ways to design modified release dosage forms for 
oral administration and one of them is multi 
layered matrix tablet [1]. One to three multi 
layered matrix tablet is a drug delivery device, 
which comprises a matrix core containing the 
active solute and one, or more barriers 
(modulating layers) incorporated during 
tabletting process [2]. The modulating layers 
delay the interaction of active solute with 
dissolution medium, by limiting the surface 
available for the solute release and at the same 
time controlling solvent penetration rate [3]. In 
the device, the coat layers prevent the water 
penetration through the protected core for some 
duration. After this phase during the subsequent 
dissolution process, the swollen barriers erode 
and surface available for drug release slowly 
increases. In this way the decrease of delivery 
rate due to increase in diffusion path length 
(saturation effect) is counter balanced by the 
simultaneous increase of the area available for 
drug release [4, 5]. Thus by combining a time-
dependent control of the hydration rate of the 
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device with the reduction of tablet surface 
exposed to the dissolution medium, it is feasible 
to achieve a linear release profile. Diclofenac 
sodium is a potent non steroidal anti 
inflammatory drug (NSAIDs) of aryl acetic acid 
class used for the treatment of degenerative joint 
disease such as osteoarthritis, anklylosing 
spondylitis, rheumatoid arthritis and also has both 
analgesic and antipyretic properties [6]. 
Diclofenac sodium has a pKa value of 4. 
Diclofenac sodium is practically insoluble in 
acidic solution, but dissolves in intestinal fluids. 
To diminish diclofenac sodium gastrointestinal 
(GI) irritation, effective enteric coating or 
sustained release dosage forms have been 
developed. Thus the present study was carried out 
to investigate the usefulness of layered matrix 
tablets in providing oral controlled drug delivery 
of diclofenac sodium. 
 
Experimental 
Materials  
Diclofenac sodium was gift sample from M/s 
(Amoli Organic Ltd., Mumbai, India. Naproxen 
gift sample from M/s (Granules India Ltd., 
Hyderabad, India) Guar gum, from H.B gums 
Kalol, Gujarat, India., Sodium Carboxy Methyl 
Cellulose (Na CMC) (high viscosity grade), was 
gift samples from Reliance Cellulose Product, 
Hyderabad. India, Hydroxy Propyl Cellulose 
(HPC) and Hydroxy Propyl Methyl Cellulose 
(HPMC K4M) were gift samples from colorcon 
Asia Pvt Ltd Goa, India. Lactose, talc, 
magnesium stearate were procured from M/s 
Loba Chime Pvt. Ltd. Mumbai. All other 
chemicals and reagents used were of analytical 
grade 
 
Method 
Preparation of matrix and layered matrix 
tablets of diclofenac sodium 
Matrix core granules were prepared by wet 
granulation process using hydrophilic polymer 
Guar gum, lactose was used as diluent, starch 
paste 10% was used as binding agent. The wet 
mass was screened through sieve no14 and the 
granules were dried at 50oC for 1hr in a tray 
dryer. The dried granules were passed through 
sieve No18 and lubricated with a mixture of talc 
and magnesium stearate. The barrier layers 
containing HPC, HPMC K4M and Na CMC 
were prepared by wet granulation method. The 
polymers and 10% starch paste were mixed well 
the resulting wet mass was passed through sieve 
no 14 and air dried at 30oC for an hour, mixed 
with talc and magnesium stearate.  
 
Compression of layered matrix tablets 
Formulation of layered matrix tablets was made 
using guar gum and drug loaded matrix core 
granules and barrier layer granules. Initially the 
volume of die cavity was adjusted equivalent to 
total weight of layered matrix tablet (400mg, 
450mg). Then pre weighed amount of barrier 
granules i.e. HPC, HPMCK4M and Na CMC 
granules equivalent to bottom layer (50mg & 
75mg) were taken and placed in the die cavity 
and slightly compressed for uniform spreading. 
The upper punch was lifted up and 300mg of 
matrix core granules were placed over the 
bottom layer of polymer granules in the die 
cavity and again slightly compressed. The 
remaining volume of die cavity was filled with 
pre weighed amount of barrier granules 
equivalent to top layer (50mg & 75mg) and 
finally compressed on a Rotary compression  
machine (Riddhi, Ahmedabad, India). The 
hardness of tablet was maintained in the range of 
4-5kg/cm2    
 
In Vitro Drug Release Study 
Drug release was studied using a dissolution 
apparatus type 2 (Lab India, DISSO 2000, 
Mumbai, India) with a shaft at a speed of 50 rpm. 
To study the effect of dissolution medium, drug 
release was studied in 900-mL HCl of pH 1.2 for 
2 hours and then the pH of medium was raised to 
6.8 by adding 4.6g Sodium hydroxide, 3.06g 
mono basic potassium phosphate and 4.005g 
dibasic sodium phosphate at 37±1°C for 12h. 
Samples were collected at specific time intervals 
and assayed by a UV spectrophotometer (Elico, 
Model SL-150, Mumbai, India.) at a wavelength 
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of 276 nm. During the drug release studies, the 
tablets were observed for physical integrity. The 
experiments were repeated three times and results 
were taken as average of three test readings with 
standard deviations. The accuracy and precision 
of the standard curve was sufficiently accurate, 
with a validated linearity for determination of 
drug in dissolution media. 
 
Analysis of release data  
The description of dissolution profiles has been 
attempted using different release models. The 
data were evaluated according to the following 
equations. 
Zero order: Mt = Mo+ Kot 
First order: ln Mt = ln Mo+ K1t 
Higuchi model: Mt = KH √t 
Korsmeyer –Peppas model: Mt/Mo = Kktn 
Where Mt is the amount of drug dissolved at time 
t, Mo the initial amount of drug,  K1is the first 
order release constant, K0 the zero order release 
constant, KH the Higuchi rate constant, Kk the 
release constant and n is the diffusional release 
exponent indicative of the operating release 
mechanism. The correlation coefficient (r2) was 
used as an indicator of the best fitting, for each of 
the models considered. 
The following equation was used to calculate the 
other dissolution parameters D.E8% and MDT 
mean dissolution data [7] 
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   ------ Eq.[1] 
Mean dissolution time (MDT) is a measure of the 
rate of the dissolution process calculated from the 
amount of drug released to the total cumulative 
drug. To compare the results of dissolution tests 
of different formulations: Dissolution efficiency 
(D.E) [8] after 8hr of release test was used.  
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----- Eq.[2] 
The similarities between two dissolution profiles 
were assessed by a pair wise model independent 
procedure similarity factor (f2). 
Similarity factor 
  --- Eq.(3) 
Where n is the sampling number, Rt and Tt are 
the percent dissolved of the reference and test 
products at each time point t. Where Wt is the 
optional weight factor (normally taken as 1).  f2 
values should be close to 100. In general f2 
values higher than 50 (50-100), show the 
similarity of dissolution profiles [7]. 
 
In vivo Bio availability Study 
Eight male volunteers, aged between 23 and 25 
years and weighing between 62 and 68kg 
participated. Studies were conducted with 
permission from the institutional ethical 
committee. The protocol of study of was 
approved by the Human Ethical Committee, 
University College of Pharmaceutical Sciences, 
Kakatiya University, India, with reference 
number UCPSc/BA/2009-06.which compiled 
ethical to the Helsinki Declaration. The purpose 
of the study was fully explained to the volunteers 
and an informed written consent was obtained 
from each volunteer. This study  was  performed  
in a  two-way  crossover  design  with a washout  
period  of  one week between two phases.  No 
other drugs were taken during the study period.  
The subjects were randomly divided into two 
groups. A light  breakfast  was  served to all 
volunteers on the study day  after overnight  
fasting,  followed by administration  of  MLT-06 
to one group  and Voveran  SR  tablet  to  another  
group  with  a glass of water after  half an  hour  
of  breakfast. No food was allowed until 4 hrs 
after dosing. Approximately 5 ml of blood 
samples were collected   at 0, 0.5, 1, 1.5, 2, 3, 4, 
6, 8, 10, 12 and 24hrs. Samples  were  
centrifuged   at  3000 rpm  for  10  minutes  and  
Serum  was stored  at  -20°c  until analyzed by 
the modified method of El-sayed et al. [9] 
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Table 1:  Formulae of matrix and layered matrix tablets with guar gum as matrix core. 
 
 
High-Performance Liquid Chromatography 
Determination of Diclofenac sodium in Human 
serum 
To each of 0.5 ml of human serum 100µl of 
naproxen (1µg) as internal standard were added 
mixed thoroughly. Then 500µl of 500mM HCl 
was added and mixed for 3 minutes. This was 
then extracted with 5ml of dichloromethane in 
vortex mixer for 5minutes and phase separation 
was achieved by centrifugation for 10 mins. From 
each sample, 4ml of organic layer was transferred 
to a test tube for removal of solvent by 
evaporation using temperature regulated vacuum 
oven. Each sample residue was reconstituted in 
0.1 ml of acetonitrile, then vortexed for one 
minute and 20µL injected into HPLC equipment. 
The operating HPLC conditions were set, and a 
stable base line was obtained on the recorder at a 
flow rate of 1ml/min. Then 20µL of the 
reconstituted solution was spiked; Peak area of 
the drug and internal standard were measured and 
their ratios were computed. The retention time of 
diclofenac and naproxen were 6.48min and 
4.50min respectively. 
 
Pharmacokinetics data analysis  
The data obtained from diclofenac serum 
concentration time profile, were analyzed for 
each subjects using non compartmental method. 
The Pharmacokinetics parameters were estimated 
by using  KINETICATM Soft ware (INNA Phase 
Corp., 2000) 
 
 
Statistical Analysis  
The data obtained was statistically analyzed using 
a using Graph pad prism version 4. (Graph pad 
prism Software, Inc). Paired t-test was used for 
comparison of all the Pharmacokinetic 
parameters. A value of P<0.05 was considered to 
be significant and results were expressed as 
mean± SD. 
 
Results and Discussion  
Physico chemical characterization of matrix 
and layered matrix tablets 
The physical parameters such as hardness was 
ranked from 4.04±0.11 kg/cm2 to 
4.99±0.12kg/cm2, thickness ranked from 
4.04±0.03mm to 6.07±0.06mm, friability ranked 
from 0.251±0.02% to 0.840±0.01%, mass of the 
tablets ranged from 301.5±0.16 to 451.0 
±1.16(mg) and drug content in the range of 
98.50± 0.78% to 103.2± 2.65% of the 
formulations. The hardness and thickness of the 
tablets were increased as the amount of barrier 
layers was increased. The hardness of layered 
matrix tablets tended to increase and friability 
decreased.  
 
In vitro drug release and kinetic 
characteristics  
Apparent drug release prolongation could be 
attained for the layered matrix tablets. The 
percentage drug release from formulations MT-
GG and MLT-01 to MLT-06 ranged from 
98.13±1.130% and 96.3±1.12% to 50.5±1.14%, 
Ingredients 
(mg)/Formulati
on  
 
Diclofenac 
Sodium 
 
Guar 
Gum 
Lactose  HPC 
 
HPMC 
K4M 
 
NaCMC 
 
Starch 
 
Talc 
 
Mg 
stearate 
MT -GG 100 100 70 - - - 18 8 4 
MLT-01 100 100 70 100 - - 18 8 4 
MLT-02 100 100 70 150 - - 18 8 4 
MLT-03 100 100 70 - 100 - 18 8 4 
MLT-04 100 100 70 - 150 - 18 8 4 
MLT-05 100 100 70 - - 100 18 8 4 
MLT-06 100 100 70 - - 150 18 8 4 
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Thus on the basis of drug release data, it is 
evident that as thickness of the polymer layer 
increased the rate of drug release was found to be 
decreased. Na CMC layered tablets (MLT-05 and 
MLT-06) provided the desired release rate 
compared to HPC and HPMC K4M layered 
tablets (MLT-02 and MLT-04), hence 
linearization has been achieved. The higher co-
relation coefficient (r2) indicated a superiority of 
the dissolution profile to the mathematical 
equations. The matrix tablets (MT GG) shows 
higher (r2) values for the first order kinetics (r2 
=0.914) Table 2, indicated that diclofenac sodium 
released from matrix tablets followed first order 
kinetics.  It was observed that the edges of layers 
were rounded off due to slight erosion of swollen 
barrier layers of HPC and HPMCK4M. The 
strength of viscous gel layer around the matrix 
core generally depends on the viscosity of the 
polymer used. The results indicated that anionic 
and pH dependent polymer Na CMC does not 
fully hydrate when placed in 0.1 N HCl, but when 
the dissolution media was replaced with pH 6.8 it 
showed rapid hydration and forms a viscous gel 
layer that forming a loose porous on the surface 
of the tablet facilitating the matrix core seeping 
of diclofenac sodium from the surfaces of the 
matrix core resulting in constant delivery of the 
drug [10]. 
 
 
Table 2. Release kinetics, MDT and DE8% of guar gum matrix and 
layered matrix tablets of diclofenac sodium. 
 
Formulation 
code 
Zero order 
release rate 
mgh-1    (r2) 
First order 
rate 
constant 
(h-1  )      (r2) 
Release 
exponent 
(n)       (k) 
DE8 
% 
MDT 
(h) 
f2 
Voveran SR 7.29 0.803 0.42 0.979 0.48 1.55 96.84 2.68 --- 
MLT-G 7.68 0.914 0.32 0.992 0.47 1.14 89.39 3.65 86.74 
MLT-01 8.11 0.973 0.36 0.985 0.59 1.38 92.52 3.83 28.18 
MLT-02 7.63 0.985 0.26 0.922 0.57 1.33 76.97 6.40 32.86 
MLT-03 6.64 0.980 0.11 0.992 0.58 1.26 81.30 6.51 36.62 
MLT-04 6.53 0.992 0.13 0.991 0.65 1.13 80.89 7.50 38.74 
MLT-05 6.12 0.996 0.10 0.996 0.81 0.95 88.30 9.19 40.37 
MLT-06 5.64 0.992 0.08 0.978 0.98 0.68 88.64 16.57 41.93 
 
The release rate patterns of all the formulations 
are given in table 2. The results suggested that the 
developed layered matrix tablets showed zero- 
order or case II release. The values of kinetic 
constant (k) were in accordance with the values 
of n, the diffusional exponents, with k having 
lower values when the mechanism was Case II 
and higher values for the formulations that 
released the drug by non-Fickian diffusion. The 
diffusional exponents (n) values for all 
formulations ranged from 0.47 to 0.98. It can be 
inferred that the release was dependent on both 
drug diffusion and polymer relaxation. It was 
observed that layered tablets swelled indicating 
that absorption of dissolution media and swelling 
process were taking place simultaneously. This 
indicates that polymer relaxation had a role in 
drug release mechanism; as a result the release of 
drug was extended for over a period of more than 
12hrs 
 
Table 3. Pharmacokinetic Parameters (mean ±sd) following 
ral administration of MLT-06 and Voveran SR o
  
Pharmacokinetic 
Parameters 
Voveran SR MLT-06 
a C max ( ng ml-1) 553.75±21.88 275.48±5.40 
a T max(hrs) 3.43±0.67 6.00±0.00 
Relative 
bioavailability (%) 
----------- 95.06 
AUC 0-∞  (ng hrs ml-
1) 
3789.84±29.62 4997.09±341.16 
a MRT (hrs) 8.16±1.48 12.72±1.28 
            a Statistical  significant (P< .05) 
 
The independent statistical evaluation, which 
involves ratio tests are dissolution efficiency 
(DE8%) and Mean dissolution time (MDT) and 
paired test is similarity factor (f2).  The data is 
shown in Table 2.  MDT and DE8% values of 
MT-GG and MLT-06 formulations were found to 
be 3.65h, 16.57h and 89.39%, 88.64% 
respectively. MDT is increased, while DE8% 
decreased, indicating the release of diclofenac 
sodium is slower, which is attributed to increase 
in the thickness of barrier layers (Na CMC) on 
the matrix core. The results of  f2 values showed 
similar dissolution profiles for  matrix tablets and 
layered tablets MT-GG (f2=86.74) and MLT-06 
(f2=41.93). Hence layered tablets showed 
dissimilar dissolution profiles as shown in Table 
2, with that of commercial (Voveran SR ) 
sustained release tablets. The layered matrix 
tablets (MLT-06) was selected as a suitable 
formulation for the bioavailability study in 
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human volunteer, since results of in-vitro release 
of MLT-06 formulation showed slower drug 
release is shown in figure 1. 
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Figure1. In-vitro dissolution profiles of matrix and layered 
matrix tablets of diclofenac sodium. 
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Figure 2. Profile of mean serum concentration versus time 
of diclofenac sodium in healthy human volunteers (n=8).  
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Figure 3.  IVIVC of layered matrix tablets MLT-06.  
 
The serum concentrations of diclofenac sodium at 
different time intervals following oral 
administration of both the formulations (Voveran 
SR and MLT-06)  (figure 2). The mean 
pharmacokinetics parameter of diclofenac sodium 
is shown in table 2. The peak serum 
concentration (C max) and time to reach peak 
concentration (Tmax) of Voveran SR and MLT-06 
were found to be 553.75ng/ml (±21.88), 3.43hrs 
(±0.67) and 275.48ng/ml (±5.40), 6.00hrs (±0.00) 
respectively. AUC0-∞ for Voveran SR and MLT-
06 were found to be 3789.84ng/ml/h (±29.62) and 
4997.09ng/ml/h (±341.16) respectively. The 
lower Cmax of formulation MLT-06, prolonged 
the Tmax. Mean residence times (MRT) of 
Voveran SR and MLT-06 formulation were 
8.16hrs and 12.72 hrs. A significant difference 
(P<0.05) was observed for the time to reach peak 
concentration Tmax and Mean residence time 
(MRT) between these two formulations. Thus 
lower C max of MLT -06, prolonged Tmax, and 
increase in AUC0-∞ shows unaltered 
bioavailability. It indicated that release of 
diclofenac sodium from MLT-06 formulation is 
slow and it may be attributed due to the longer 
residence time in the GIT, there by providing a 
controlled and effective absorption of diclofenac 
sodium. In vitro-In vivo correlation was done by 
plotting percentage drug absorbed versus in vitro 
drug release. The plot was linear for the layered 
matrix tablet (MLT-06) with a correlation 
coefficient of 0.913, indicating high correlation 
(figure3). This in vitro-in vivo correlation is of 
great use in developing controlled release tablets 
[11]. 
 
Conclusion  
The layered matrix tablets (MLT-06) can be a 
useful alternative formulation in comparison with 
matrix type Voveran SR tablet. It was observed 
that Voveran SR tablets could n’t with stand GI 
movements and released the diclofenac sodium 
quickly with in 3hrs, resulting in faster 
absorption. There by it produces high peak 
concentration Cmax with earlier Tmax, when 
compared to layered matrix MLT-06. Guar Gum 
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dispersed matrix core layered with 75mg of Na 
CMC on both the surfaces as barrier layers were 
found to be useful to achieve controlled release of 
diclofenac sodium through out the 
gastrointestinal tract. 
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